John Mendlein steps in to help focus on the big picture at a fast-growing Moderna
Two months ago John Mendlein passed the reins at aTyr, quietly stepping away from a company he had run for 6 years.
This morning, he’s back in a much more visible position.
Stéphane Bancel has named Mendlein as the new company president at biotech unicorn Moderna, with responsibility for corporate and product strategy. It’s an unusual move for a biotech like Moderna, which is still navigating the early stages of clinical development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
